You are here

Article Text

Article menu
Download PDFPDF
Original research
Validation of the QLQ-CX24 questionnaire for the assessment of quality of life in Mexican women with cervical cancer
  1. Julissa Luvián-Morales1,
  2. Laura Flores-Cisneros1,
  3. Roberto Jiménez-Lima1,
  4. Silvia Alarcón-Barrios1,
  5. Jessica Salazar-Mendoza1,
  6. Denisse Castro-Eguiluz2,
  7. Lucely Cetina-Pérez1 and
  8. Luis F Oñate-Ocaña1
  1. 1 Subdirección de Investigación Clínica, Instituto Nacional de Cancerología, Mexico City, Tlalpan, Mexico
  2. 2 Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico City, Mexico
  1. Correspondence to Dr Luis F Oñate-Ocaña, Instituto Nacional de Cancerología, Mexico, Mexico; lfonate{at}gmail.com; Dr Lucely Cetina-Pérez, Subdirección de Investigación Clínica, Instituto Nacional de Cancerología, Mexico City, Mexico; lucelycetina.incan{at}gmail.com

Abstract

Objective Cervical cancer is the fourth most frequent neoplasm among women in terms of incidence and mortality. Health-related quality of life (HRQL) is an important outcome in oncology. The QLQ-CX24 instrument was developed to measure HRQL in patients with cervical cancer, and its Mexican-Spanish version had not been validated.

Methods Between March 2018 and May 2019, Mexican women older than 18, with any-stage cervical cancer were invited to participate in the study. Patients answered the QLQ-C30 and QLQ-CX24 questionnaires. Current tests for psychometric and clinical validation were performed.

Results Three hundred and thirty patients with cervical cancer were included in this study. All women invited to participate accepted and were included. The QLQ-CX24 internal consistency test demonstrated adequate convergent (Spearman correlation coefficient 0.001–0.847) and divergent validity (Spearman correlation coefficient <0.0001–0.45). Cronbach’s alpha coefficients of the three multi-item scales were >0.7 (minimum 0.76, maximum 0.89). Four scales of the QLQ-CX24 distinguished patients in different clinical stages. The evaluation of responsiveness demonstrated that the peripheral neuropathy scale was sensitive to change over time during chemo-radiation therapy. Six scales of the QLQ-CX24 instrument were associated with survival.

Conclusion The Mexican-Spanish version of the QLQ-CX24 questionnaire is reliable and valid for the assessment of HRQL in patients with cervical cancer.

  • cervical cancer
  • quality of life (PRO)/palliative care

Data availability statement

Data are available upon reasonable request.

https://doi.org/10.1136/ijgc-2021-002720

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request.

    View Full Text

    Footnotes

    • Contributors JLM designed the study, participated in the follow‐up of patients, constructed the database, analyzed the data, interpreted and discussed the results, and wrote and edited the final version of the manuscript. LFC constructed the database, and conducted the study and follow‐up of patients. RJL designed and conducted the study. SEAB constructed the database and participated in the data analysis. JSM participated in the construction of the database. DCE edited the final version of the manuscript. LCP designed the study, analyzed, and interpreted the patient data, analyzed, and discussed results, and wrote and edited the final version of the manuscript. LFOO designed the study, analyzed, and interpreted the patient data, analyzed, and discussed results, and wrote and edited the final version of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.